Issue 2, 2023

Anticancer evaluation of new organometallic ruthenium(ii) flavone complexes

Abstract

Targeting multiple malignancy features such as angiogenesis, proliferation and metastasis with one molecule is an effective strategy in developing potent anticancer agents. Ruthenium metal complexation to bioactive scaffolds is reported to enhance their biological activities. Herein, we evaluate the impact of Ru chelation on the pharmacological activities of two bioactive flavones (1 and 2) as anticancer candidates. The novel Ru complexes (1Ru and 2Ru) caused a loss of their parent molecules' antiangiogenic activities in an endothelial cell tube formation assay. 1Ru enhanced the antiproliferative and antimigratory activities of its 4-oxoflavone 1 on MCF-7 breast cancer cells (IC50 = 66.15 ± 5 μM and 50% migration inhibition, p < 0.01 at 1 μM). 2Ru diminished 4-thioflavone's (2) cytotoxic activity on MCF-7 and MDA-MB-231 yet significantly enhanced 2's migration inhibition (p < 0.05) particularly on the MDA-MB-231 cell line. The test derivatives also showed non-intercalative interaction with VEGF and c-myc i-motif DNA sequences.

Graphical abstract: Anticancer evaluation of new organometallic ruthenium(ii) flavone complexes

Supplementary files

Article information

Article type
Research Article
Submitted
02 Sep 2022
Accepted
22 Nov 2022
First published
15 Dec 2022
This article is Open Access
Creative Commons BY license

RSC Med. Chem., 2023,14, 253-267

Anticancer evaluation of new organometallic ruthenium(II) flavone complexes

M. Khater, J. A. Brazier, F. Greco and H. M. I. Osborn, RSC Med. Chem., 2023, 14, 253 DOI: 10.1039/D2MD00304J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements